Antigens – Talk Bio

Actionable Insights Powered by AI

Gilead Sciences Acquires Investigational HIV Vaccine Assets from AELIX Therapeutics

5 months ago talkbio0Tagged Antigens, Gilead Sciences, HIV Vaccine, HIVACAT, HTI

Gilead Sciences, AELIX Therapeutics, HIV vaccine, HTI immunogen, IrsiCaixa, HIVACAT program

AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success

11 months ago talkbio0Tagged AbbVie, Antibody-Drug Conjugates, Antigens, Elahere, ovarian neoplasm, Phase 2 Clinical Trials, Return on Investment, ROI

AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere

AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment

11 months ago talkbio0Tagged AbbVie, Acquisition (action), Antibody-Drug Conjugates, Antigens, Clinical Trials, Elahere, Neoplasms, ovarian neoplasm

AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

11 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.